Keywords
Pregnant women
Psychotropics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the reasons, risks and benefits of the use of Psychotropic Drugs (FP) in pregnant women. Methods: This is an integrative literature review, between 2019-2022, from the MEDLINE, SciELO and LILACS databases through descriptors in Portuguese and English, with full text available for reading. A total of 213 articles were identified, of which 91 met the inclusion and exclusion criteria. After reading and critical analysis, 11 articles were chosen to compose the sample universe of this review. Results: Major depressive disorder was the most prevalent reason for medical prescription during pregnancy with 36.2%. In addition, an average of 26.55% of the pregnant women used some psychotropic drug during the pregnancy period. The most used drug classes were in this order: tricyclic antidepressants (TCA), anxiolytics and Selective Serotonin Reuptake Inhibitors (SSRIs). The presence of major fetal adverse effects associated with FP was verified, such as Ebstein's anomaly, neonatal abstention syndrome (NAS) and low birth weight. Final considerations: It was found that the safety of prescribing FP during pregnancy is not yet well understood, however, there are studies that have already proven that some drugs are less teratogenic, preserving the health of the mother-baby binomial.
References
ABEL KM. Exposição antipsicótica fetal em um cenário em mudança: vendo o futuro. Br J Psiquiatria, 2013; 202(5): 321‐323.
AMORIM I, et al. Evaluation of the use of psychoactive drugs during the period of pregnancy and lactation. Revista INOVALE, 2020; 1.
ANZAI T, et al. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis. BMC Psychiatry, 2020; 20(1): 118.
AYANO G, et al. Prevalence and determinants of antenatal depression in Ethiopia: A systematic review and meta-analysis. PLoS ONE, organizado por Astrid M. Kamperman, 2019; 14(2): e 0211764.
BADHAN RKS e MACFARLANE H. Quetiapine dose optimisation during gestation: a fármaco kinetic modelling study. J Pharm Pharmacol., 2020; 72(5): 670-681.
BARROS KBNT, et al. Vista do Percepção de discentes de farmácia e enfermagem de uma instituição de ensino superior sobre a utilização de psicofármacos na gestação. Revista de Ciências Médicas e Biológicas, 2017.
BETCHER HK e WISNER KL. Tratamento psicotrópico durante a gravidez: Síntese de pesquisa e princípios de cuidados clínicos. Revista de Saúde da Mulher, 2020; 310-318.
BIESDORF C, et al. Physiologically-based pharmacokinetics of ziprasidone in pregnant women. Br J Clin Pharmacol. 2019 May;85(5):914-923.
BRASIL. Relação Nacional de medicamentos Essenciais. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde Departamento de Assistência Farmacêutica e Insumos Estratégicos. Ministério da Saúde, Brasília-DF, 2022.
DAVE CV, et al. Prevalence of Maternal-Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015. Pharmacotherapy, 2019; 39(10): 1005-1011.
DELL’OSBEL RS, et al. Sintomas depressivos em gestantes da atenção básica: prevalência e fatores associados. ABCS Health Sciences, 2019; 44: 3.
GALBALLY M, et al. Psychopharmacological prescribing practices in pregnancy for women with severe mental illness: A multicentre study. European Neuropsychopharmacology, 2019; 29(1): 57– 65.
GUSTAFSSON HC, et al. Transtorno depressivo maior durante a gravidez: Os medicamentos psiquiátricos têm efeitos mínimos no feto e no bebê, mas o desenvolvimento é comprometido. Development and Psychopathology, 2018; 30(3): 773–785.
HANLEY GE, et al. A Cohort Study of Psychotropic Prescription Drug Use in Pregnancy in British Columbia, Canada from 1997 to 2010. J Womens Health (Larchmt), 2020; 29(10): 1339-1349.
KESKIN DD, et al. Mental disorders among pregnant women during the COVID-19 pandemic. A cross- sectional study. Sao Paulo Med J., 2022; 140(1): 87-93.
LEITE LMGS e CATÃO CDS. Teratogênese e ácido valpróico: revisão da literatura. Campina Grande: Realize Editora, 2016.
LIU X, et al. Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score-matched cohort study. PLoS Med, 2022 ; 19(1).
MASTERS GA, et al. Utilization of Health Care Among Perinatal Women in the United States: The Role of Depression. J Womens Health (Larchmt), 2020; 29(7): 944-951.
MONGAN D, et al. Prevalence of self-reported mental disorders in pregnancy and associations with adverse neonatal outcomes: a population-based cross-sectional study. BMC Pregnancy Childbirth, 2019; 19(1): 412.
MOLENAAR NM, et al. Lambregtse-van den Berg MP, Bonsel GJ. Padrões de distribuição de inibidores seletivos de recaptação de serotonina antes, durante e após a gravidez: um estudo de coorte de base populacional de 16 anos na Holanda. Arch Womens Ment Health, 2020; 23 (1): 71– 9.
PAULINO D, et al. Gestantes internadas no hospital psiquiátrico: um retrato da vulnerabilidade. Physis: Revista De Saúde Coletiva, 2022 32(1).
OLIVEIRA IR. Antipsicóticos atípicos: farmacologia e uso clínico. Braz J Psychiatry, 2000; 22suppl1.
SILVA MMJ, et al. Anxiety in pregnancy: prevalence and associated factors*. Revista Da Escola De Enfermagem Da USP, 2017; 51.
SILVA DR. “Uso inadvertido de medicamentos psicotrópicos na comunidade de Guarda-Mór em São João Del Rei - MG” - Biblioteca Virtual do NESCON. Ufmg.br. 2014.
RAYBURN WF. Pregnancy: An Opportune Time to Evaluate and Treat Mental Health Disorders. Obstetrics and Gynecology Clinics of North America, v. 45, n. 3, p. xiii–xiv, 2018.
SHIFFMAN D, et al. Concordância de Fatores de Risco Cardiovascular e Comportamentos em uma Coorte Multiétnica Nacional dos EUA de Casais e Parceiros Domésticos. JAMA Netw Open. 2020; 3(10): e2022119.
SUZUKI S E KATO M. Deterioração/recaída da depressão durante a gravidez em mulheres japonesas associada à interrupção de medicamentos antidepressivos. J Matern Fetal Neonatal Med., 2017; 30( 10): 1129–32
SUN F, et al. Uma revisão sistemática envolvendo 11.187 participantes avaliando o impacto do COVID-19 na ansiedade e depressão em mulheres grávidas. J Psychosom Obstet Gynaecol., 2021; 42 (2): 91–99.
URIARTE JJ, et al. Uso de medicação antipsicótica na gravidez. Uso Psiquiatría Biológica, 2018; 25(3): 103–107.
WISNER KL, et al. Bipolar disorder and psychotropic medication: Impact on pregnancy and neonatal outcomes. J Affect Disord., 2019; 243: 220-225.